Loading patent…
AssigneeAlba Therapeutics Corporation
InventorsSefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
Estimating the term…
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.
A peptide permeability inhibitor consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:1-162, wherein said peptide permeability inhibitor inhibits translocation of a gliadin-derived peptide across a biological barrier.
A method of inhibiting gliadin-derived peptide translocation across a biological barrier comprising contacting said barrier with a peptide permeability inhibitor consisting of an amino acid sequence selected from the group consisting of SEQ IDF NOs:1-162.
A composition for inhibiting gliadin-derived peptide translocation across a biological barrier, wherein said composition comprises a peptide permeability inhibitor consisting of an amino acid sequence selected from the group consisting of SEQ IDF NOs:1-162.
A peptide consisting of an amino acid sequence selected from the group consisting of SEQ IDF NOs:1-162, wherein said peptide inhibits a gliadin-induced increase in biological barrier permeability.
A method of inhibiting a gliadin-induced increase in biological barrier permeability comprising contacting said barrier with a peptide permeability inhibitor consisting of an amino acid sequence selected from the group consisting of SEQ IDF NOs:1-162.
A composition for inhibiting a gliadin-induced increase in biological barrier permeability, wherein said composition comprises a peptide permeability inhibitor consisting of an amino acid sequence selected from the group consisting of SEQ IDF NOS:1-162.
A method of treating a patient with celiac disease, comprising administering to the patient a composition comprising a peptide that inhibits translocation of a gliadin-derived peptide across a biological barrier.
A method of treating a patient with diabetes, comprising administering to the patient a composition comprising a peptide that inhibits a gliadin-induced increase in biological barrier permeability.
A method of treating a patient with dermatitis herpetiformis, comprising administering to the patient a composition comprising a peptide that inhibits translocation of a gliadin-derived peptide across a biological barrier.
Dependencies are inferred from the claim text.